Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.36 |
| ▸ | SPHK2 | Q9NRA0 | 1/20 | 0.33 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.33 |
| ▸ | BRD4 | O60885 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 2/20 | 0.31 |
| ▸ | CA2 | P00918 | 2/20 | 0.31 |
| ▸ | CA4 | P22748 | 2/20 | 0.31 |
| ▸ | CA9 | Q16790 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3429290 | 1.00 | SIGMAR1 (0.36) | SIGMAR1SPHK2SPHK1BRD4CA1 | |
| SCHEMBL3426954 | 0.89 | SIGMAR1 (0.35) | SIGMAR1SPHK2SPHK1BRD4 | |
| SCHEMBL3428790 | 0.84 | SIGMAR1 (0.41) | SIGMAR1SPHK2SPHK1BRD4CA1 | |
| SCHEMBL3429294 | 0.84 | SIGMAR1 (0.41) | SIGMAR1SPHK2SPHK1BRD4CA1 | |
| SCHEMBL21210556 | 0.82 | GAA (0.42) | SIGMAR1SPHK2SPHK1 | |
| SCHEMBL3426958 | 0.81 | SIGMAR1 (0.39) | SIGMAR1SPHK2SPHK1 | |
| SCHEMBL24319356 | 0.80 | SIGMAR1 (0.38) | SIGMAR1SPHK2SPHK1BRD4 | |
| SCHEMBL19072490 | 0.80 | SIGMAR1 (0.38) | SIGMAR1SPHK2SPHK1BRD4 | |
| SCHEMBL24319162 | 0.80 | SIGMAR1 (0.38) | SIGMAR1SPHK2SPHK1BRD4 | |
| SCHEMBL25141784 | 0.79 | GBA2 (0.45) | SPHK2SPHK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7691867-B2 | Chemical compounds | ASTRAZENECA AB (SE) | 2010-04-06 | — | — | US | disclosed |
| EP-1613619-B1 | QUINAZOLINE DERIVATIVES FOR TREATMENT OF CANCER | ASTRAZENECA AB (SE) | 2008-03-26 | — | — | EP | disclosed |
| US-20060270692-A1 | Chemical compounds | ASTRAZENECA AB (SE) | 2006-11-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060270692-A1 | Chemical compounds | CCNI, MKI67, TP53 | SIGMAR1 3443/4885SPHK2 2879/4885SPHK1 2758/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.